PDF(Pubmed)
Abstract：
Imeglimin has not been well studied as an oral agent for the treatment of latent autoimmune diabetes of adults (LADA). We treated 2 cases of LADA with imeglimin. The case 1 patient was originally diagnosed with type 2 diabetes (T2D) at age 50 years and was treated with sulfonylurea, biguanide, canagliflozin, imeglimin, and dulaglutide. Before imeglimin, his glycated hemoglobin A1c (HbA1c) change was 94.0 mmol/mol (8.6%) in November 2022, but it dropped to 71.0 mmol/mol (6.5%) in May 2023 after imeglimin was added. The case 2 patient was originally diagnosed with T2D when she was aged 48 years. She was treated with vildagliptin, biguanide, luseogliflozin, and imeglimin. Her HbA1c before imeglimin was 92.9 mmol/mol (8.5%) in January 2023, which decreased to 75.4 mmol/mol (6.9%) in July 2023 after imeglimin was added. Although imeglimin has not been approved for treating type 1 diabetes and LADA, adding imeglimin to the current medication was effective in improving and controlling the patients\' plasma glucose.
摘要：
尚未将Imeglimin作为治疗成人隐匿性自身免疫性糖尿病（LADA）的口服药物进行很好的研究。我们用伊米霉素治疗了2例LADA。病例1患者最初在50岁时被诊断为2型糖尿病（T2D），并接受磺脲类药物治疗。双胍,Canagliflozin,imeglimin,还有dulaglutide.在imeglimin之前,2022年11月,他的糖化血红蛋白A1c(HbA1c)变化为94.0mmol/mol(8.6%),但在加入伊美美素后,其变化在2023年5月降至71.0mmol/mol(6.5%).病例2患者最初在48岁时被诊断为T2D。她接受了维格列汀治疗,双胍,Luseogliflozin,还有imeglimin.2023年1月，她在imeglimin之前的HbA1c为92.9mmol/mol（8.5％），在添加imeglimin后，到2023年7月降至75.4mmol/mol（6.9％）。尽管imeglimin尚未被批准用于治疗1型糖尿病和LADA，在目前的药物中加入伊美霉素可有效改善和控制患者的血糖。
